Posts

Merck Advances Winrevair to Phase 3 with Preference for Lower Dose in Rare Heart Failure Trial

on

Merck Makes Strong Case for Winrevair in Earlier-Stage Pulmonary Arterial Hypertension (PAH) Patients After Positive Phase 3 HYPERION Results

on

Merck's Winrevair Slashes Morbidity and Mortality Risk in Pulmonary Arterial Hypertension

on

ACC25: Merck & Co.'s Winrevair reduces mortality in most severe PAH patients

on

Merck Halts HYPERION Trial of Winrevair Early Due to Overwhelming Efficacy in PAH Treatment

on